127 related articles for article (PubMed ID: 37605506)
41. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
42. Stimuli-responsive nanoparticles for the codelivery of chemotherapeutic agents doxorubicin and siPD-L1 to enhance the antitumor effect.
Zhou YJ; Wan WJ; Tong Y; Chen MT; Wang DD; Wang Y; You BG; Liu Y; Zhang XN
J Biomed Mater Res B Appl Biomater; 2020 May; 108(4):1710-1724. PubMed ID: 31746127
[TBL] [Abstract][Full Text] [Related]
43. Gene augmented nuclear-targeting sonodynamic therapy via Nrf2 pathway-based redox balance adjustment boosts peptide-based anti-PD-L1 therapy on colorectal cancer.
Wan G; Chen X; Wang H; Hou S; Wang Q; Cheng Y; Chen Q; Lv Y; Chen H; Zhang Q
J Nanobiotechnology; 2021 Oct; 19(1):347. PubMed ID: 34715867
[TBL] [Abstract][Full Text] [Related]
44. Multifunctional Mesoporous Silica-Coated Gold Nanorods Mediate Mild Photothermal Heating-Enhanced Gene/Immunotherapy for Colorectal Cancer.
Li M; Yang J; Yao X; Li X; Xu Z; Tang S; Sun B; Lin S; Yang C; Liu J
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986715
[TBL] [Abstract][Full Text] [Related]
45. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment.
Zhang P; Qin C; Liu N; Zhou X; Chu X; Lv F; Gu Y; Yin L; Liu J; Zhou J; Huo M
Biomaterials; 2022 May; 284():121518. PubMed ID: 35462305
[TBL] [Abstract][Full Text] [Related]
46. Reactive glia promote development of CD103
Prasad S; Hu S; Sheng WS; Chauhan P; Lokensgard JR
Immun Inflamm Dis; 2018 Jun; 6(2):332-344. PubMed ID: 29602245
[TBL] [Abstract][Full Text] [Related]
47. Engineered Hybrid Treg-Targeted Nanosomes Restrain Lung Immunosuppression by Inducing Intratumoral CD8
Domvri K; Petanidis S; Zarogoulidis P; Anestakis D; Charalampidis C; Tsavlis D; Huang H; Freitag L; Hohenforst-Schmidt W; Matthaios D; Katopodi T; Porpodis K
Int J Nanomedicine; 2022; 17():4449-4468. PubMed ID: 36172007
[TBL] [Abstract][Full Text] [Related]
48. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
49. Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro.
Tay WT; Fang YH; Beh ST; Liu YW; Hsu LW; Yen CJ; Liu PY
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244307
[TBL] [Abstract][Full Text] [Related]
50. Augmented Antitumor Effect of Unripe
Lee EJ; Yang JH; Choi JG; Chung HS
Cells; 2022 Sep; 11(18):. PubMed ID: 36139451
[TBL] [Abstract][Full Text] [Related]
51. Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy.
Guan X; Lin L; Chen J; Hu Y; Sun P; Tian H; Maruyama A; Chen X
J Control Release; 2019 Jan; 293():104-112. PubMed ID: 30476528
[TBL] [Abstract][Full Text] [Related]
52. Dual mitigation of immunosuppression combined with photothermal inhibition for highly effective primary tumor and metastases therapy.
Huang J; Zhang L; Zhou W; Wang J; Zhang R; Wang Z; Ran H; Li P; Li R
Biomaterials; 2021 Jul; 274():120856. PubMed ID: 33984634
[TBL] [Abstract][Full Text] [Related]
53. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
[TBL] [Abstract][Full Text] [Related]
54. Bioactive fatty acid analog-derived hybrid nanoparticles confer antibody-independent chemo-immunotherapy against carcinoma.
Tan X; Wang C; Zhou H; Zhang S; Liu X; Yang X; Liu W
J Nanobiotechnology; 2023 Jun; 21(1):183. PubMed ID: 37291573
[TBL] [Abstract][Full Text] [Related]
55. Rationally designed peptide-conjugated gold/platinum nanosystem with active tumor-targeting for enhancing tumor photothermal-immunotherapy.
Yang Q; Peng J; Shi K; Xiao Y; Liu Q; Han R; Wei X; Qian Z
J Control Release; 2019 Aug; 308():29-43. PubMed ID: 31252039
[TBL] [Abstract][Full Text] [Related]
56. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
57. Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer.
Zhao P; Xu Y; Ji W; Zhou S; Li L; Qiu L; Qian Z; Wang X; Zhang H
J Nanobiotechnology; 2021 Jun; 19(1):181. PubMed ID: 34120612
[TBL] [Abstract][Full Text] [Related]
58. Vascular Normalization Was Associated with Colorectal Tumor Regression upon Anti-PD-L1 Combinational Therapy.
Zhang Y; Gao J; He Y; Qi Z; Qian L; Chen W; Xu H; Yue Y; Mao X; Guo S; Zhou Y; Zhou S; Qin S; Zhang X; Huang Y
J Immunol Res; 2023; 2023():5867047. PubMed ID: 36969495
[TBL] [Abstract][Full Text] [Related]
59. Human Vγ9Vδ2 T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells.
Tomogane M; Sano Y; Shimizu D; Shimizu T; Miyashita M; Toda Y; Hosogi S; Tanaka Y; Kimura S; Ashihara E
Biochem Biophys Res Commun; 2021 Oct; 573():132-139. PubMed ID: 34407491
[TBL] [Abstract][Full Text] [Related]
60. Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy.
He ZD; Zhang M; Wang YH; He Y; Wang HR; Chen BF; Tu B; Zhu SQ; Huang YZ
Acta Pharmacol Sin; 2021 Sep; 42(9):1516-1523. PubMed ID: 33311600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
